



SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplax, Premium Retail, Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.

E-mail : compliance@sudarshanpharma.com, Website : www.sudarshanpharma.com

Board Line : +91-22-42221111 / 43331111/42221116 (100 line) CIN: L51496MH2008PLC184997

SPIL/CS/SE/2025-2026/38

Date: 5th August 2025

To,

The Listing Department

BSE Limited

Phiroze Jeejeebhoy Towers,

Dalal Street, Mumbai – 400 001

BSE Scrip Code: 543828

BSE Trading Symbol: SUDARSHAN

ISIN: INE00TV01023

Sub: Updates on acquisition of the shares of Cibachem General Trading LLC, Dubai

Ref: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

Dear Sir / Madam,

In continuation of the Company's disclosure dated 16th January 2025 (SPIL/CS/SE/2024-2025/54), regarding approval of the Board to acquire 300 shares of AED 1,000/- each of M/s. Cibachem General Trading L.L.C., Dubai, United Arab Emirates, (License no.: 696207) (referred to as 'Cibachem'), pursuant to Regulation 30 of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), this is to inform you that the Company has acquired the said 300 shares of Cibachem.

Consequent to the aforesaid acquisition, Cibachem has become a wholly-owned subsidiary of the Company.

The details as required under the SEBI Listing Regulations read with SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July 2023 are given in Annexure A.

This is for your information and record.

Thanks & Regards,

Yours faithfully,

For, Sudarshan Pharma Industries Limited

Hemal Mehta

Chairman & Managing Director



Encl: As above



SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplax, Premium Retail, Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.

E-mail : compliance@sudarshanpharma.com, Website : www.sudarshanpharma.com

Board Line : +91-22-42221111 / 43331111/42221116 (100 line) CIN: L51496MH2008PLC184997

Annexure A

Details required under Regulation 30 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 read with SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July 2023 are given below:

Sl. No.	Details to be Provided	Information
1	Name of the target entity, details in brief such as size, etc.	Name: Cibachem General Trading L.L.C. (Cibachem) Cibachem General Trading L.L.C, a limited liability company established originally under the name "Benjamin International General Trading L. L. C. under The Federal Law no. 8 of 1984 and registered with the Department of Economic Development of the Emirate of Dubai under commercial license no. 696207 and attested by the Notary Public under serial no. 172562/1/2013 on 30 th September 2013.
2	Whether the acquisition would fall within related party transactions and whether the promoter / promoter group / group companies have any interest in the entity being acquired? If yes, nature of the interest and details thereof and whether the same is done at 'arm's length'	No. The acquisition would not fall within the related party transactions.
3	Industry to which the entity being acquired belongs.	Cibachem was established to carry on the business of general trading which shall include the carrying on of all activities as are related or ancillary thereto except that Cibachem cannot carry on the business of insurance, banking or investment of funds for the account of third parties.
4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The acquisition of Cibachem will enable the Company to enlarge its customer base in the Middle East Region.
5	Brief details of governmental or any regulatory approvals "required for the acquisition	Approval of the Reserve Bank of India under Foreign Exchange Management Act, 1999 Foreign Exchange Management (Overseas Investment), Rules, Regulations and Directions, 2022 as may be amended from time to time (approval under automatic route).
6	Indicative time period for completion of the acquisition	Not Applicable





SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplax, Premium Retail, Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.

E-mail : compliance@sudarshanpharma.com, Website : www.sudarshanpharma.com

Board Line : +91-22-42221111 / 43331111/42221116 (100 line) CIN: L51496MH2008PLC184997

7	Nature of Consideration whether Cash consideration or share swap and details of the same	Consideration for acquiring shares of Cibachem done in cash.												
8	Cost of acquisition or the price at which the shares are acquired.	Rs.55,00,000/- only (Rupees Fifty Five Lakhs only) or its equivalent in UAE Dirhams (AED).												
9	Percentage of shareholding control acquired and / or number of shares acquired	300 equity shares of AED 1000/- each (100.00% of the paid-up share capital) of Cibachem from the following shareholders: 1. Mr. Nilesh Harish Thakkar – 225 shares (75%) 2. Mrs. Hina Harish Thakkar – 54 shares (18%) 3. Mr. Benjamin Harish Thakkar – 21 shares (7%)												
10	Brief background about the entity acquired in terms of products/ line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	<u>Brief background:</u> Cibachem General Trading L.L.C, a limited liability company registered with the Department of Economic Development of the Emirate of Dubai under commercial license no. 696207 and attested by the Notary Public under serial no. 172562/1/2013 on 30 th September 2013. Turnover of the Cibachem for the last three financial years is given below: <table><thead><tr><th></th><th>Turnover (in AED)</th><th>PAT (in AED)</th></tr></thead><tbody><tr><td>For year ended 31-12-2022</td><td>4,92,588</td><td>82,979</td></tr><tr><td>For year ended 31-12-2023</td><td>3,51,050</td><td>1,51,746</td></tr><tr><td>For year ended 31-12-2024</td><td>4,99,250</td><td>2,54,008</td></tr></tbody></table>		Turnover (in AED)	PAT (in AED)	For year ended 31-12-2022	4,92,588	82,979	For year ended 31-12-2023	3,51,050	1,51,746	For year ended 31-12-2024	4,99,250	2,54,008
	Turnover (in AED)	PAT (in AED)												
For year ended 31-12-2022	4,92,588	82,979												
For year ended 31-12-2023	3,51,050	1,51,746												
For year ended 31-12-2024	4,99,250	2,54,008												

For, Sudarshan Pharma Industries Limited

Hemal Mehta
Chairman & Managing Director

